Table 1.
Basic characteristics of included studies.
| Author/Year/Ref | Country | Leukemia | Vaccination | |||
|---|---|---|---|---|---|---|
| Type | Number | Method of Diagnosis | Type | Time | ||
| Crispen/1976 | USA | ND | 85356 | ND | BCG | ND |
| Dockerty/1999 | New Zealand | ALL | 121 | ND | BCG, MMR, Measles, Rubella, Oral Polio, DPT, Double vaccine, Hepatitis B | BCG: 3 months, 6 years, Measles: within 1 year |
| Nishi/1989 | Japan | ALL | 63 | ND | BCG and Measles | 1st and 2nd year |
| Groves/1999 | USA | ALL | 439 | ND | MMR,Oral Polio, DPT, Tetanus, Diphteria, Hib polysaccharide and conjugate, Hepatitis B | ND |
| Von Kries/2000 | Germany | AL | 129 | ND | BCG, MMR | BCG: at birth, MMR: after 1 year |
| MacArthur/2007 | Canada | ND | 399 | Hematology, Pathology | Mumps, Measles, Rubella, Diphtheria, Pertussis,Tetanus, Polio, Hepatitis, BCG, and others | 1st and 2nd year |
| Mallol.Mesnard/2007 | France | AML, ALL, AL | 726 | Bone marrow analysis | BCG, Diphtheria, Tetanus, Poliomyelitis, Pertussis, Hepatitis B, Hib, Pneumococcus, Meningococcus, Measles, Mumps, Rubella | 1st and 2nd year |
| Ma/2005 | USA | ND | 323 | ND | DTP, MMR, Polio, Hepatitis B, and Hib | ND |
| Petridou/1997 | Greece | ND | 153 | ND | DTP, BCG, Virus vaccines | At birth |
| Salonen/1976 | Finland | ND | 368 | Pathology, Clinical | BCG | 1–18 year |
| Comstock/1975 | USA | ND | 98 | ND | BCG | ND |
| Davignon/1971 | Canada | ND | 96 | ND | BCG | ND |
| Máthé/1974 | France | ND | 130 | ND | BCG | ND |
| Sutherland/1982 | England | ND | 28 | ND | BCG, vole-bacillus | ND |